Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6H10O4 |
Molecular Weight | 146.1412 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CO1)[C@H](O)[C@H](O)[C@]2([H])CO2
InChI
InChIKey=AAFJXZWCNVJTMK-GUCUJZIJSA-N
InChI=1S/C6H10O4/c7-5(3-1-9-3)6(8)4-2-10-4/h3-8H,1-2H2/t3-,4+,5+,6-
Dianhydrogalactitol (VAL-083 or NSC-132313) a cytostatic sugar derivative, is alpha,omega-substituted hexitol acting as bifunctional alkylating agent. It induces interstrand crosslinks at N7 guanines leading to doublestrand breaks and HR activation independent of MGMT, and mediating cell cycle arrest through p53-dependent and p53-independent pathways. Dianhydrogalactitol is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and lung cancer. The drug has not been approved for any indication outside of China. DelMar Pharmaceuticals is developing dianhydrogalactitol for the treatment of intracranial tumors.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7387628 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: http://www.delmarclinicaltrials.com/ |
Primary | Unknown Approved UseUnknown |
||
Primary | DIANHYDROGALACTITOL Approved UseDianhydrogalactitol (VAL-083) is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia ("CML") and lung cancer. |
|||
Primary | DIANHYDROGALACTITOL Approved UseDianhydrogalactitol (VAL-083) is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia ("CML") and lung cancer. |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT03149575
In a Phase 3 clinical trial a total of up to 180 eligible patients with recurrent/progressive patients with glioblastoma multiforme (GBM) or gliosarcoma (GS) will be randomized to receive either dianhydrogalactitol (VAL-083) or "Investigator's choice of salvage therapy" as a contemporaneous control, in a 2:1 fashion. Up to 120 eligible patients will be randomized to receive VAL-083 at 40 mg/m2 IV on days 1, 2, and 3 of a 21-day treatment-cycle, for up to 12, 21-day treatment cycles or until they fulfill one of the criteria for study discontinuation.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28216618
Treatment with 1,2:5,6-dianhydrogalactitol (DAG) (120 μmol/L) dose-dependently inhibited the proliferation and colony formation in human glioma cell lines LN229, U251, and U87MG in vitro. DAG (1, 2, 5 μmol/L) induced cell cycle arrest at G2/M phase in the 3 glioma cell lines in a dose-dependent manner.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/12/1093
Created by
admin on Fri Dec 15 15:36:46 UTC 2023 , Edited by admin on Fri Dec 15 15:36:46 UTC 2023
|
||
|
FDA ORPHAN DRUG |
903822
Created by
admin on Fri Dec 15 15:36:46 UTC 2023 , Edited by admin on Fri Dec 15 15:36:46 UTC 2023
|
||
|
FDA ORPHAN DRUG |
361311
Created by
admin on Fri Dec 15 15:36:46 UTC 2023 , Edited by admin on Fri Dec 15 15:36:46 UTC 2023
|
||
|
FDA ORPHAN DRUG |
514915
Created by
admin on Fri Dec 15 15:36:46 UTC 2023 , Edited by admin on Fri Dec 15 15:36:46 UTC 2023
|
||
|
NCI_THESAURUS |
C475
Created by
admin on Fri Dec 15 15:36:46 UTC 2023 , Edited by admin on Fri Dec 15 15:36:46 UTC 2023
|
||
|
FDA ORPHAN DRUG |
512515
Created by
admin on Fri Dec 15 15:36:46 UTC 2023 , Edited by admin on Fri Dec 15 15:36:46 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
132313
Created by
admin on Fri Dec 15 15:36:46 UTC 2023 , Edited by admin on Fri Dec 15 15:36:46 UTC 2023
|
PRIMARY | |||
|
AB-48
Created by
admin on Fri Dec 15 15:36:46 UTC 2023 , Edited by admin on Fri Dec 15 15:36:46 UTC 2023
|
PRIMARY | |||
|
23261-20-3
Created by
admin on Fri Dec 15 15:36:46 UTC 2023 , Edited by admin on Fri Dec 15 15:36:46 UTC 2023
|
PRIMARY | |||
|
9908
Created by
admin on Fri Dec 15 15:36:46 UTC 2023 , Edited by admin on Fri Dec 15 15:36:46 UTC 2023
|
PRIMARY | |||
|
D003961
Created by
admin on Fri Dec 15 15:36:46 UTC 2023 , Edited by admin on Fri Dec 15 15:36:46 UTC 2023
|
PRIMARY | |||
|
C425
Created by
admin on Fri Dec 15 15:36:46 UTC 2023 , Edited by admin on Fri Dec 15 15:36:46 UTC 2023
|
PRIMARY | |||
|
CHEMBL3137322
Created by
admin on Fri Dec 15 15:36:46 UTC 2023 , Edited by admin on Fri Dec 15 15:36:46 UTC 2023
|
PRIMARY | |||
|
100000178203
Created by
admin on Fri Dec 15 15:36:46 UTC 2023 , Edited by admin on Fri Dec 15 15:36:46 UTC 2023
|
PRIMARY | |||
|
DTXSID90878831
Created by
admin on Fri Dec 15 15:36:46 UTC 2023 , Edited by admin on Fri Dec 15 15:36:46 UTC 2023
|
PRIMARY | |||
|
DB12873
Created by
admin on Fri Dec 15 15:36:46 UTC 2023 , Edited by admin on Fri Dec 15 15:36:46 UTC 2023
|
PRIMARY | |||
|
4S465RYF7M
Created by
admin on Fri Dec 15 15:36:46 UTC 2023 , Edited by admin on Fri Dec 15 15:36:46 UTC 2023
|
PRIMARY | |||
|
15942827
Created by
admin on Fri Dec 15 15:36:46 UTC 2023 , Edited by admin on Fri Dec 15 15:36:46 UTC 2023
|
PRIMARY |
ACTIVE MOIETY